Framework Ventures IV L.P. and Related Entities File Form 3 for NovaBay Pharmaceuticals, Inc.

Framework Ventures IV L.P., along with Framework Ventures Management LLC, Framework Ventures IV GP LLC, Michael Ernest Anderson, and Vance Spencer, have jointly filed a Form 3 with the SEC regarding their ownership in NovaBay Pharmaceuticals, Inc. The filing discloses the purchase of Series D and Series E Non-Voting Convertible Preferred Stock by Framework Ventures IV L.P. from David Lazar and other investors. The Series D Preferred Stock is convertible into a maximum of 1,164,117 shares of common stock, and the Series E Preferred Stock is convertible into 134,375 shares of common stock. The conversion of these shares is contingent upon stockholder approval of certain proposals at the annual meeting held on October 16, 2025. The filing also includes a Joint Filing Agreement, indicating that the entities are jointly responsible for the completeness and accuracy of the information provided.